Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Agronomics losses rise but company hails portfolio progress

(Sharecast News) - Cellular agriculture and biomanufacturing investor Agronomics saw losses swell in its first half but reported significant technological and commercial progress for the year, with shares rising on Friday. The company reported a net loss of £6.56m for the six months to 31 December, compared with a loss of £0.44m the year before, as net investment losses totalled £5.87m compared with net investment income of £0.39m previously.

The company's net asset value per share fell 4.1% over the period to 14.93p, though the share price at the half (3.88p) stood at a 74% discount to NAV.

Agronomics' portfolio companies have now raised nearly $400m in total since August 2023, with many of the more mature assets achieving some of the largest financing rounds in the sector, the company said.

"The progress we have achieved during a challenging period for much of the cultivated proteins industry pays testament to the quality of our portfolio and our ability to identify the future category leaders within the industry," said chair James Mellon.

Looking ahead, Mellon predicted a "transformative year" for the portfolio, with a number of companies up for regulatory approvals or reaching commercialisation.

Shares were up 1% at 6.87p by 1155.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.